SFTPC and acute respiratory distress syndrome: After recombinant SP-C based surfactant (Venticute®, Nycomed GmbH, Konstanz, Germany) failed to improve oxygenation in a recent randomized clinical trial because of insufficient surface activity (Spragg et al., 2004; Spragg et al., 2011), doubts have risen about the rationale for exogenous surfactant treatment in ALI/ARDS (Brower & Fessler, 2011; Dushianthan et al., 2012).